Comparative Pharmacology
Head-to-head clinical analysis: PANCURONIUM BROMIDE versus ZEMURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANCURONIUM BROMIDE versus ZEMURON.
PANCURONIUM BROMIDE vs ZEMURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thus inhibiting muscle contraction.
Rocuronium is a nondepolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor endplate, preventing acetylcholine from inducing muscle contraction.
0.04-0.1 mg/kg IV initial bolus, then 0.01-0.02 mg/kg IV every 20-40 min as needed for neuromuscular blockade.
0.6-1.2 mg/kg IV bolus for intubation; maintenance 0.1-0.2 mg/kg IV as needed for neuromuscular blockade.
None Documented
None Documented
Terminal elimination half-life: 100-120 minutes in adults with normal renal function; prolonged to 240-480 minutes in renal failure.
Terminal elimination half-life is approximately 2.3 hours (range 1.7-3.1 hours) in adults with normal renal function. Clinical context: May be prolonged in hepatic or renal impairment.
Renal: 50-70% unchanged; biliary/fecal: 5-10% as metabolites; minor hepatic metabolism.
Primarily renal (70-80% as unchanged drug and metabolites) and biliary (20-30% as unchanged drug and metabolites).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent